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Antiarrhythmic Effects of Simvastatin
in Canine Pulmonary Vein Sleeve Preparations
Serge Sicouri, MD, Brittany Gianetti, BS, Andrew C. Zygmunt, PHD, Jonathan M. Cordeiro, PHD,
Charles Antzelevitch, PHD
Utica, New York
Objectives The purpose of this study was to determine the electrophysiologic effects of simvastatin in canine pulmonary
vein (PV) sleeve preparations.
Background Ectopic activity arising from the PV plays a prominent role in the development of atrial fibrillation.
Methods Transmembrane action potentials were recorded from canine superfused left superior or inferior PV sleeves us-
ing standard microelectrode techniques. Acetylcholine (1 M), isoproterenol (1 M), high calcium ([Ca2]o 
5.4 mM), or a combination was used to induce early afterdepolarizations or delayed afterdepolarizations and
triggered activity. Voltage clamp experiments were performed in the left atrium measuring fast and late sodium
currents.
Results Under steady-state conditions, simvastatin (10 nM, n  9) induced a small increase in action potential duration
measured at 85% repolarization and a significant decrease in action potential amplitude, take-off potential, and
maximum rate of rise of action potential upstroke at the fastest rates. The Vmax decreased from 175.1  34 V/s
to 151.7  28 V/s and from 142  47 V/s to 97.4  39 V/s at basic cycle lengths of 300 and 200 ms, respec-
tively. Simvastatin (10 to 20 nM) eliminated delayed afterdepolarizations and delayed afterdepolarization-
induced triggered activity in 7 of 7 PV sleeve preparations and eliminated or reduced late-phase 3 early afterde-
polarizations in 6 of 6 PV sleeve preparations. Simvastatin (20 nM) did not affect late or fast sodium currents
measured using voltage clamp techniques.
Conclusions Our data suggest that in addition to its upstream actions to reduce atrial structural remodeling, simvastatin exerts
a direct antiarrhythmic effect by suppressing triggers responsible for the genesis of atrial fibrillation. (J Am Coll
Cardiol 2011;57:986–93) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.08.649Since their discovery in Japan in the mid-1970s, 3-hydroxy-
3-methyl-glutaryl-CoA reductase inhibitors (statins) have
been widely used to reduce low-density lipoprotein (LDL)
and total cholesterol. Other beneficial cardiovascular effects,
in addition to those involving the lipid profile, have been
attributed to statins. These so-called pleiotropic effects are
mainly related to the anti-inflammatory and potential anti-
arrhythmic effects of statins, particularly in the setting of
atrial fibrillation (AF) (1). Experimental studies have shown
that statins attenuate atrial electrical remodeling induced by
atrial tachypacing and can thus prevent the creation of the
substrate for development of AF (2). Simvastatin was shown
to greatly attenuate the effect of tachypacing to down-
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accepted September 23, 2010.regulate the L-type Ca2 channel -subunit (Cav1.2) ex-
pression. A number of randomized and large observational
clinical studies have reported beneficial effects of statins in
AF, particularly in the setting of heart failure. Treatment
with statins was linked to a decreased incidence or recur-
rence of AF in patients with a history of AF, patients
undergoing cardiac surgery, post-ablation, patients im-
planted with a pacemaker or implantable cardioverter-
defibrillator, or in patients with acute coronary syndrome
(3–7). To the best of our knowledge, no controlled clinical
studies have been performed evaluating the acute effect of
simvastatin on atrial fibrillation.
See page 994
Ectopic activity arising from the pulmonary veins (PV) has
been shown to play an important role in the development of
AF (8). Late-phase 3 early afterdepolarization (EAD)-induced
as well as delayed afterdepolarization (DAD)-induced trig-
c
r
1
i
c
s
c
t
T
i
f
n
s
c
l
t
o
r
c
i
s
t
N
g
P
(
u
d
e
p
w
a
c
i
w
(
t
r
(
p
s
s
s
t
o
s
t
f
I
A
f
(
a
n
n
m
L
p
m
i
1
c
s
V
E
m
M
i
q
p
s
f
i
(
s
s
t
c
a
w
987JACC Vol. 57, No. 8, 2011 Sicouri et al.
February 22, 2011:986–93 Effect of Simvastatin in Pulmonary Vein Sleevesgered activity originating from PV sleeves have been proposed
as potential triggers in the initiation of AF (9–15).
The present study was designed to test the hypothesis
that simvastatin’s ameliorative effects on AF are in part
mediated by its actions to suppress triggered activity arising
from PV sleeves.
Methods
This investigation conforms to the “Guide for Care and Use of
Laboratory Animals” published by the National Institutes of
Health (NIH publication no. 85-23, revised 1996) and was
approved by the Animal Care and Use Committee of the
Masonic Medical Research Laboratory.
Adult mongrel dogs, weighing 20 to 35 kg, were antico-
agulated with heparin (180 IU/kg) and anesthetized with
sodium pentobarbital (35 mg/kg, intravenously). The chest
was opened through a left thoracotomy, and the heart
excised and placed in a cold cardioplegic solution ([K]0 
8 mmol/l, 4oC).
Superfused PV sleeve preparation. The PV sleeve prepa-
rations (approximately 2.0 1.5 cm) were isolated from left
anine atria. The canine PV sleeve model consists of a small
ectangular section of cardiac muscle, approximately 2 cm by
.5 cm and 1-mm to 2-mm thick. The preparation is
solated from the left atrium adjacent to the PV. The vein is
ut open so that muscle and vein lay flat, thus exposing the
urface area from which to record action potentials under
ontrol conditions and after exposure to the different solu-
ions used in the study. The tissue is superfused with normal
yrode solution or Tyrode solution containing simvastatin,
soproterenol, high calcium, or their combinations. There-
ore, the different drugs diluted in the Tyrode solution are
ot directly perfused through the pulmonary vein and
hould not experience mechanical interference through
ompetitive flow.
Similar to the findings in the human heart (16), histo-
ogical studies performed in the canine heart have shown
hat sleeves of endocardium penetrate the proximal section
f the PV (17,18). In this study, action potentials were
ecorded from the endocardial extension of atrial muscle
overing the PVs. Left superior PVs were used preferentially
n most experiments. The preparations were placed in a
mall tissue bath and superfused with Tyrode’s solution of
he following composition (in mM): 129 NaCl, 4 KCl, 0.9
aH2PO4, 20 NaHCO3, 1.8 CaCl2, 0.5 MgSO4, and 5.5
lucose, buffered with 95% O2/5% CO2 (35  0.5
oC). The
V preparations were stimulated at a basic cycle length
BCL) of 1,000 ms during the equilibration period (1 h)
sing electrical stimulation (1 to 3 ms duration, 2.5 times
iastolic threshold intensity) delivered through silver bipolar
lectrodes insulated except at the tips. Transmembrane
otentials were recorded using glass microelectrodes filled
ith 3 M KCl (10 to 20 M DC resistance) connected to
high input-impedance amplification system (World Pre-
ision Instruments, model KS-700, New Haven, Connect- mcut). The following parameters
ere measured: take-off potential
TOP), action potential ampli-
ude (APA), action potential du-
ation at 85% repolarization
APD85), and maximal rate of
rise of action potential upstroke
(Vmax). Transmembrane action
otentials were recorded at a
ampling rate of 41 kHz. Mea-
urement of TOP was used in-
tead of resting membrane po-
ential because the slow phase 3
f the action potential of the PV
leeve preparation fails to return
o the resting potential at the
astest rates.
solated myocyte preparation.
trial myocytes were prepared
rom canine hearts using techniques described previously
19). Briefly, male and female adult mongrel dogs were
nesthetized with sodium pentobarbital (35 mg/kg intrave-
ously), and their hearts were rapidly removed and placed in
ominally Ca2-free Tyrode’s solution. The left atria were
excised, cannulated through the ostium and perfused with
nominally Ca2-free Tyrode’s solution containing 0.1%
bovine serum albumin (BSA) for a period of about 5 min.
The atria was then subjected to enzyme digestion with the
nominally Ca2-free solution supplemented with 0.5
g/ml collagenase (Type II, Worthington Biochemicals,
akewood, New Jersey) and 1 mg/ml BSA for 30 min. After
erfusion, tissue from the appendage and the pectinate
uscle were isolated, placed in separate beakers, minced and
ncubated in fresh buffer containing 0.5 mg/ml collagenase,
mg/ml BSA and agitated. The supernatant was filtered,
entrifuged and the pellet containing the myocytes was
tored at room temperature.
oltage clamp recordings of peak sodium current (INa).
arly INa was measured as previously described (19) with
inor modifications. Experiments were performed using a
ultiClamp 700A (AXON Instruments, Foster City, Cal-
fornia). Command voltages were delivered and data ac-
uired using a DigiData 1322 computer interface using the
Clamp 9 program suite (AXON Instruments) with data
tored on computer hard disk. Patch pipettes were pulled
rom borosilicate glass (1.5 mm outer diameter and 1.1 mm
nner diameter) on a Model PP-830 vertical puller
Narashige Instruments, Tokyo, Japan). The electrode re-
istance was 1 to 2.5 M when filled with the internal
olution (see the following text). The membrane was rup-
ured by applying negative pressure and series resistance
ompensated by 75% to 80%. Whole cell current data was
cquired at 20 to 50 kHz and filtered at 5 kHz. Currents
ere normalized to cell capacitance. All peak INa experi-
Abbreviations
and Acronyms
ACh  acetylcholine
AF  atrial fibrillation
APD85  action potential
duration measured at 85%
repolarization
BCL  basic cycle length
DAD  delayed
afterdepolarization
EAD  early
afterdepolarization
ICa  calcium current
INa  sodium current
PV  pulmonary vein
Vmax  maximal rate of rise
of action potential upstrokeents were performed at 15° C.
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Effect of Simvastatin in Pulmonary Vein Sleeves February 22, 2011:986–93External solution contained the following (in mM):
NMDG 105, NaCl 40, CaCl2 2.0, MgCl2 1, glucose 10,
nd HEPES 10, pH adjusted to 7.4 with HCl. The pipette
olution contained (mM) NaCl 5, aspartate 120, MgCl2 1,
CsCl 5, HEPES 10, MgATP 5, and EGTA 10, pH
adjusted to 7.2 with CsOH. Peak sodium current was
dramatically reduced in the low extracellular sodium to
ensure adequate voltage control. Cells were held at 90 or
120 mV before evoking a train of 15 100-ms pulses to
30 mV with a diastolic interval of 100 ms.
Voltage clamp recordings of late INa. Late INa density was
measured in full external Na at 37° C as previously
escribed (20). External solution contained (in mM) NaCl
40, CaCl2 2.0, MgCl2 1, glucose 10, and HEPES 10, pH
adjusted to 7.4 with NaOH. The pipette solution contained
(mM) NaCl 10, aspartate 130, MgCl2 1, CsCl 10, HEPES
10, MgATP 5, and EGTA 10, pH adjusted to 7.2 with
CsOH.
Late INa density was recorded in cells that were held at90
V. Currents were recorded during a train of 15 pulses. To
emove steady-state inactivation, a 160- or 200-ms pulse to
120 mV was taken before a 200-ms pulse to 30 mV.
imvastatin at concentrations of 20 nM or 5 M was applied
and the train repeated, followed by 10 M tetrodotoxin. Late
INa, characterized as the tetrodotoxin-sensitive difference cur-
rent, was measured as the total charge moved beginning 15 ms
after the start of the step to 30 mV.
Whole cell currents were analyzed using the Clampfit
nalysis program from pClamp 9 suite (AXON Instruments).
rugs. Simvastatin was dissolved in dimethyl sulfoxide to
orm a stock solution of 100 M and used at a final
oncentration of 10 to 20 nM. Isoproterenol (Sigma-
ldrich, St. Louis, Missouri) was dissolved in distilled water
o form a stock solution of 1 mM and used at final
Figure 1 Effect of Simvastatin in a Pulmonary Vein Sleeve Prep
(A) Control action potentials recorded at basic cycle lengths (BCLs) of 2,000, 500
Simvastatin accentuated the depolarization and reduction of take-off potential obsoncentrations of 1 and 0.5 M. It should be noted that a
revious study performed in rabbit myocytes (21) used
activated” simvastatin (22) to measure calcium as well as
ransient outward currents. We used activated simvastatin to
easure sodium currents and repeated experiments evalu-
ting the effects of activated simvastatin in PV sleeve
reparations. Similar results were observed with activated
nd nonactivated forms of simvastatin; therefore, the data
ere pulled together in the results section. Acetylcholine
ACh) was dissolved in distilled water to form a stock
olution of 10 mM and used at a concentration of 1 M.
Statistics. Electrophysiological data are presented as mean 
SD. Statistical analysis of action potential data obtained in
the presence and absence of drug was performed using
paired t test, and statistical comparisons of voltage-clamp
data were made using analysis of variance followed by a
Student Newman-Keuls test. Mean values were considered
to be statistically different at p  0.05.
Results
Effects of simvastatin on PV sleeve preparations. Simv-
astatin (10 nM) accentuated the depolarization and reduc-
tion of take-off potential normally observed in PV sleeve
preparations with rapid rates of activation (Fig. 1). The
more positive take-off potential at the faster rates is due to
a small simvastatin-induced increase in the duration of
action potential caused by a slowing of the final part of
phase 3. Composite data show a small increase in APD85
and a significant decrease in APA, TOP, and Vmax at the
astest rates (Table 1, Fig. 2). Our findings indicate that
imvastatin induces a marked use-dependent depression of
max in PV sleeve preparations.
on
300 ms. (B) Effect of simvastatin (10 nM).
in the pulmonary vein sleeve at fast rates.arati
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February 22, 2011:986–93 Effect of Simvastatin in Pulmonary Vein SleevesEffects of simvastatin on DAD- and EAD-induced triggered
activity. In another series of experiments, we determined
he effects of simvastatin on DADs, late-phase 3 EADs, and
riggered activity elicited by exposure of the PV sleeve
reparations to ACh, isoproterenol, high [Ca2], or their
combination and rapid pacing. Simvastatin (10 to 20 nM)
eliminated DADs and DAD-induced triggered activity in 7
of 7 PV sleeve preparations (Fig. 3). Simvastatin (10 to 20
nM) eliminated late phase 3 EADs and triggered activity in
6 of 6 PV sleeve preparations (Fig. 4). Simvastatin also
Rate-Dependent Effects of Simvastatin (10 nM) on ElectrophysioloTable 1 Rate-Dependent Effects of Simvastatin (10 nM) on Ele
2,000 1,000
APD85, ms
Control 160.1 20 150.5 14
Simvastatin 162.8 24 153.7 19
APA, mV
Control 111.2 7 110.8 6
Simvastatin 109.4 8 108.4 7
TOP, mV
Control 81.8 4 81.2 4
Simvastatin 81.5 5 80.2 5
Vmax, V/s
Control 211.1 35 209.4 36
Simvastatin 211.0 36 204.6 36
*p  0.05 simvastatin versus control; n  9.
APA action potential amplitude; APD85 action potential duration at 85% repolarization; BCL
Figure 2 Rate-Dependent Effects of Simvastatin on Vmax in Pul
(A) Control recording of maximal rate of rise of action potential upstroke (Vmax) re
monary vein sleeve preparation. (B) Effect of simvastatin (10 nM). (C) Composite
expressed as values normalized to a BCL of 2,000 ms. Acceleration from a BCL o
27.5% decrease after addition of simvastatin (p  0.05). A change in BCL from 2
decrease upon addition of simvastatin (p  0.05).suppressed ACh (1 M) and high calcium (5.4 mM)
nduced late phase 3 EADs observed in alternate beats at
apid pacing rates (Fig. 5).
ffects of simvastatin on late and fast sodium currents.
igure 6 shows that INa, late was unaffected by 5 M
simvastatin; Figure 6A shows INa, late in control solutions
nd 4 min after applying the drug. While exposed to the
rug, the diastolic interval was abbreviated from 200 ms to
60 ms, and the currents in Figure 6B were recorded. In the
resence of 5 M simvastatin, INa, late was unaffected by
Parametershysiological Parameters
BCL, ms
500 300 200
135.8 17 119.1 23 104.3 23
141.1 17 126.2 13 112.1 15
109.2 6 106.0 6 99.8 5
107.2 7 102.9 8 91.0 9*
80.5 3 78.6 4 76.8 3
78.1 4* 75.5 4* 71.6 6*
197.4 35 175.1 34 142 47
183.6 30* 151.7 28* 97.4 39*
c cycle length; TOP take-off potential; Vmaxmaximum rate of rise of action potential upstroke.
ry Vein Sleeve Preparations
at basic cycle lengths (BCLs) of 2,000, 1,000, 500, 300, and 200 ms in a pul-
n  9) of effects on Vmax expressed in absolute values. (D) Effects on Vmax
0 to 300 ms led to a 16.8% decrease of Vmax under control conditions and a
o 200 ms produced a 33.1% decrease under control conditions and a 54%gicalctropmona
corded
data (
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Effect of Simvastatin in Pulmonary Vein Sleeves February 22, 2011:986–93shortening the diastolic interval. Figure 7 summarizes the
xperiments showing that early and late INa were unaffected
by 20 nM simvastatin.
Discussion
Atrial fibrillation is the most common arrhythmia requiring
medical attention. Ectopic activity arising from the PV
sleeves is thought to be an important source of triggers and,
in some cases, substrate for the development of AF (23–25).
The results of the present study indicate that concentrations
of simvastatin within the therapeutic range (8 to 20 nM)
(17,26) induce rate-dependent depression of Vmax in canine
V sleeve preparations. Our results also indicate that sim-
astatin suppresses DADs, late-phase 3 EADs, and trig-
ered activity induced in PV sleeves by the addition of
Figure 3 Effect of Simvastatin to Suppress
Isoproterenol-Induced DAD and Triggered Activity
(A) Induction of delayed afterdepolarization (DAD) and triggered response after a
train of 20 beats at basic cycle lengths (BCLs) of 120 and 110 ms, respectively,
in the presence of isoproterenol. (B) Simvastatin (10 nM) eliminates the triggered
beat and reduces DAD amplitude. (C) Simvastatin (20 nM) eliminates the trig-
gered beat as well as DAD activity. (D) Washout of simvastatin restores trig-
gered activity.soproterenol, acetylcholine, high calcium, or their combi-ation. These data suggest a direct antiarrhythmic effect of
imvastatin, in addition to the previously described up-
tream therapeutic effect.
imvastatin eliminates EAD- and DAD-induced triggered
ctivity in PV sleeves. The present study shows that late-
hase 3 EADs and DADs can be easily induced in PV
leeve preparations after the addition of isoproterenol, ACh,
nd high calcium, alone or in combination. Similar findings
ere previously reported by Chen et al. (17,27) in canine
nd rabbit isolated single PV myocytes, by Patterson et al.
12,13) in isolated canine PV sleeve preparations, and by
urashnikov et al. (11,28) in coronary-perfused right atrial
reparations. In isolated myocytes, isoproterenol was shown
o increase automaticity and induce spontaneous as well as
AD- or DAD-induced triggered activity (17,27). Late-
hase 3 EADs and late-phase 3 EAD-induced triggered
ctivity (11,28) is a relatively new concept of arrhythmo-
enesis. Abbreviated repolarization permits normal sarco-
lasmic reticulum calcium release and associated sodium-
alcium exchange inward current to induce a late-phase 3
AD, resulting in closely coupled triggered responses when
t reaches threshold. Conditions permitting intracellular
alcium loading facilitate the development of late-phase 3
Figure 4 Simvastatin Eliminates
Late-Phase 3 EADs and Triggered Activity
(A) Effect of acetylcholine (ACh), 1 M, and high calcium, 5.4 mM, to induce
late-phase 3 early afterdepolarizations (EADs) and triggered activity after a train
of 20 beats at a basic cycle length (BCL) of 200 ms. (B) Simvastatin, 10 nM,
suppresses EADs and triggered activity. (C) Washout of simvastatin restores
triggered activity.
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February 22, 2011:986–93 Effect of Simvastatin in Pulmonary Vein SleevesEADs. Patterson et al. (12,13) showed that autonomic
stimulation could give rise to this phenomenon in canine
PV sleeves and in some cases result in a run of triggered
responses.
Our data illustrate that simvastatin in concentrations of
10 nM and 20 nM (within its therapeutic range) is able to
eliminate late-phase 3 EADs and DAD-induced triggered
activity arising from these 2 mechanisms. Similar findings
were reported for ranolazine, an antianginal agent with a
potent effect to cause use-dependent depression of so-
dium channel activity at rapid rates, similar to that of
simvastatin (9).
Ionic mechanisms. In isolated mouse ventricular myo-
cytes, simvastatin has been shown to inhibit the late ICa,
Figure 5
Effect of Simvastatin to Suppress
Late Phase 3 EADs Elicited at Rapid
Stimulation Rates (BCL  150 ms)
(A) ACh, 1 M, and high calcium, 5.4 mM, induce late phase 3 EAD in alter-
nate beats. (B) Simvastatin, 10 nM, eliminates late phase 3 EADs. Abbrevia-
tions as in Figure 4.
Figure 6 Late Sodium Currents Unaffected by Simvastatin
(A) Currents recorded during a train of 15 pulses in control solution (left) and in 5
(B) In the presence of 5 M simvastatin, rate dependence of drug was investigatealthough at much higher concentrations (IC50 50 mol/l)
(21). The data point to a lack of an effect of simvastatin on
either early (peak) and late sodium currents in canine atrial
cells despite a significant effect of the drug to reduce Vmax in
V sleeves at fast rates (BCL of 500, 300, and 200 ms). The
ecrease in Vmax may be explained by a simvastatin-induced
epolarization and a more positive take-off potential at the
aster rates due to a small simvastatin-induced increase in
he duration of action potential caused by a slowing of the
nal part of phase 3. Additional studies will be necessary to
stablish the ionic basis for this change. Suppression of
AD and late-phase 3 EAD activities by simvastatin can be
xplained by its actions to reduce intracellular sodium
oading, which occurs at rapid activation rates. By doing so,
imvastatin reduces calcium loading, which normally occurs
nder these conditions as a result of sodium-calcium ex-
hange (29–31). The effects may also have been explained
y an effect of simvastatin to block calcium current (21).
omparison of simvastatin with traditional antiarrhythmic
rugs. The antifibrillatory action of most antiarrhythmic
gents used to treat AF has been ascribed chiefly to their
bility to induce prolongation of the effective refractory
eriod, by prolonging APD (i.e., dl-sotalol and dofetilide),
educing excitability (i.e., flecainide and propafenone), or by
combined mechanism (i.e., amiodarone and ranolazine).
n experimental studies, multiple ion-channel blockers, like
miodarone and ranolazine, act by prolonging effective
efractory period both by increasing APD as well as by
roducing a marked depression of excitability, thus inducing
ost-repolarization refractoriness especially at rapid activa-
ion rates (use-dependent effect) (32,33).
Compared to these traditional antiarrhythmic agents,
imvastatin produces little change in APD, but does induce
depression of Vmax and excitability at rapid rates, although
not as accentuated as in the case of chronic amiodarone
(34,35). This action of simvastatin is most similar to that of
imvastatin (right) at a diastolic interval of 200 ms.
hortening the diastolic interval to 160 ms.M s
d by s
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Effect of Simvastatin in Pulmonary Vein Sleeves February 22, 2011:986–93class IB antiarrhythmic agents such as lidocaine. The effects
of simvastatin on EADs and DAD-induced triggered ac-
tivity are similar to those of ranolazine (9). Chronic amio-
darone has also been shown to prevent the development of
EADs, DADs, and triggered activity induced by exposure
to isoproterenol, ACh, high calcium, or their combination
(10,35). Thus, the actions of simvastatin on the triggers of
AF (DAD- or EAD-induced triggered activity) are similar
to those of traditional antiarrhythmic drugs, whereas its
effects on the substrate are less pronounced. These findings
suggest that further studies examining the efficacy of a
combination of statins with antiarrhythmic agents in the
Figure 7 Early and Late INa in the
Presence of 20 nM Simvastatin
Currents were normalized to the corresponding current recorded in control solu-
tion. (A) Normalized fast sodium current (INa) as a function of pulse number
recorded from a holding potential of 90 mV (A, n  11 atrial cells, p  0.05)
or 120 mV (B, n  11 atrial cells, p  0.05). (C) Late INa in the presence of
20 nM simvastatin as a function of pulse number (n  11 atrial cells, p 
0.05). Late INa was measured as the area delimited by the dotted lines.management of AF, may be warranted.Clinical implications: antiarrhythmic effects of statins.
Statins are the most common drugs used in the clinical
treatment of hypercholesterolemia. Patients administered
statins for their lipid-lowering actions may benefit from
their upstream effects (36), which are related to anti-
inflammatory actions as well as their direct effects to
minimize electrical remodeling (37). Clinical (38) and
experimental studies point to a prominent role of PVs in the
genesis of atrial arrhythmias, including AF (8,27). Our data
suggest that in addition to its upstream effects and direct
actions to reduce electrical remodeling during rapid activa-
tion of the atria, simvastatin can suppress late-phase 3
EADs, DADs, and triggered activity induced in PV sleeves.
Interestingly, other agents with upstream actions, such as
the antihypertensive agents losartan and enalapril, have also
been shown in preliminary reports to eliminate DADs and
late phase 3 EAD-induced triggered activity in PV sleeves
(39). Our findings suggest that simvastatin, and perhaps
other statins, may exert an important antiarrhythmic effect
to suppress the triggers that contribute to the development
of AF. Further clinical studies are warranted to evaluate the
role of statins in the prevention and treatment of atrial
arrhythmias, including AF.
Conclusions
Our data suggest that in addition to its upstream actions to
reduce atrial structural remodeling, simvastatin exerts a
direct antiarrhythmic effect by suppressing triggers respon-
sible for the genesis of AF.
Reprint requests and correspondence: Dr. Serge Sicouri, Ma-
sonic Medical Research Laboratory, 2150 Bleecker Street, Utica,
New York 13501-1787. E-mail: sicouris@mmrl.edu.
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